Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) rose 25.4% this week, according to data from S&P Global Market Intelligence . The stock closed at $17.66 a share on Friday, then opened at $17.70 on Monday. The company's shares rose throughout the week, going as high as $22....
Shares of BioXcel Therapeutics (BTAI +15.2%) are up significantly today and have been on a roll this week ahead of an April 5 FDA action date on BXCL501, its candidate for agitation in bipolar disorder and schizophrenia. The stock is up ~24% since the start of trading on Monday. Ear...
We are initiating coverage on BTAI with a target price of USD 126 (+600% potential upside) and a potential 60% downside (~$7 cash value). We like the risk-reward set-up for the company. Our investment thesis/key catalyst revolves around the April 5th PDUFA date for BXCL501; we believe...
BioXcel Therapeutics, Inc. (BTAI) Q4 2021 Earnings Conference Call March 10, 2022 08:30 ET Company Participants Vimal Mehta - Founder, President & Chief Executive Officer Richard Steinhart - Senior Vice President & Chief Financial Officer Robert Risinger - Vice President of Clinical D...
Shares of BioXcel Therapeutics (BTAI -5.7%) are trading down even though the company's Q4 2021 earnings beat on the bottom line. BioXcel's (BTAI -5.7%) net loss widened in the quarter ~24% to $26.1M (-$0.93 net loss per share, basic and diluted) compared to the prior-year period. The company ...
BioXcel Therapeutics press release (NASDAQ:BTAI): Q4 GAAP EPS of -$0.93 beats by $0.21. As of December 31, 2021, cash and cash equivalents totaled approximately $233.0M. For further details see: BioXcel Therapeutics GAAP EPS of -$0.93 beats by $0.21
Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Submitted IND to evaluate BXCL501 as adju...
AFCG, AG, AMTX, ATY, AUTL, BBW, BTAI, BZUN, CCLP, DCBO, DESP, DLTH, EMAN, ENG, ESTE, EVGN, EXK, FCEL, GNCA, GWRS, JD, KNOP, LAZY, LIZI, ML, NEON, OTCQX:QTRHF, SELB, SHIP, TEO, THRY, TXMD, UP, VITL, XERS For Seeking Alpha's full earnings season calendar, click here. For further details see: ...
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, ...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...